Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Enterprise Value (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Enterprise Value for 15 consecutive years, with -$737.0 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value rose 17.5% year-over-year to -$737.0 million; the TTM value through Mar 2026 reached -$737.0 million, up 17.5%, while the annual FY2025 figure was -$854.4 million, 4.4% up from the prior year.
  • Enterprise Value hit -$737.0 million in Q1 2026 for Agios Pharmaceuticals, up from -$854.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$569.9 million in Q2 2024 and bottomed at -$1.0 billion in Q3 2024.
  • Average Enterprise Value over 5 years is -$797.8 million, with a median of -$783.1 million recorded in 2022.
  • Year-over-year, Enterprise Value soared 60.46% in 2022 and then plummeted 64.76% in 2025.
  • Agios Pharmaceuticals' Enterprise Value stood at -$783.1 million in 2022, then increased by 0.79% to -$776.9 million in 2023, then fell by 15.03% to -$893.7 million in 2024, then rose by 4.4% to -$854.4 million in 2025, then increased by 13.74% to -$737.0 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$737.0 million, -$854.4 million, and -$952.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.